Evaluation of possible risk factors of lamivudine resistance in chronic hepatitis B patients: A retrospective study in Iran

Hepatitis Monthly

Volumn 9, Issue 3, 2009, Pages 171-179

  Bidgoli, Sepideh Arbabi ^a   Daryani, Nasser Ebrahimi ^b   Motamedi, Maryam ^a   Miri, Atoosa ^a   Poorsamimi, Parisa ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Iranian Charity for Hepatic Patients Support   (Iran)

Author keywords

Chronic Hepatitis B; Cross resistance; Glutathione S transferas pi; Interferon alpha; Lamivudine

Indexed keywords

ALPHA INTERFERON; ASPARTIC ACID; BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE P1; LAMIVUDINE; METHIONINE; TYROSINE;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CASE CONTROL STUDY; CHILD; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRAN; LIVER BIOPSY; MALE; PREDICTION; RELIABILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCHOOL CHILD; SCORING SYSTEM; TISSUE LEVEL;

EID: 70350754344     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bahramali G, Sadeghizadeh M, Amini-Bavil-Olyaee S, et al. Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients. World J Gastroenterol. 2008;14(35):5448-5453
2. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61-68
3. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362(9401):2089-2094
4. Pallier C, Castera L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006;80(2):643-653 (Pubitemid 43062877)
5. Chieochansin T, Chutinimitkul S, Payungporn S, et al. Rapid detection of lamivudine-resistant hepatitis B virus mutations by PCR-based methods. Tohoku J Exp Med. 2006;210(1):67-78. (Pubitemid 44377791)
6. Hoofnagle JH. Hepatitis B - preventable and now treatable. N Engl J Med. 2006;354(10):1074-1076
7. Mohammad Alizadeh AH, Ranjbar M, Karimi B, Hatami S. Biochemical response to lamivudine treatment in HBeAg negative chronic hepatitis B patients in Iran. World J Gastroenterol. 2006;12(26):4203-4205 (Pubitemid 44376903)
8. Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol. 2005;43(1):72-77
9. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119(1):172-180
10. Orito E, Fujiwara K, Tanaka Y, et al. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res. 2006;35(2):127-134 (Pubitemid 43758356)
11. Alexander G, Baba CS, Chetri K, Negi TS, Choudhuri G. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial. BMC Gastroenterol. 2005;5:29. (Pubitemid 41418964)
12. Nishinaka T, Ichijo Y, Ito M, et al. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol Lett. 2007;170(3):238-247 (Pubitemid 46710275)
13. Yusof YA, Yan KL, Hussain SN. Immunohistochemical expression of pi class glutathione S-transferase and alpha-fetoprotein in hepatocellular carcinoma and chronic liver disease. Anal Quant Cytol Histol. 2003;25(6):332-338
14. Shen LJ, Zhang ZJ, Zhang HX, Yang WB, Huang R. [Expression of GST-pi and HBV infection in hepatocellular carcinoma]. Ai Zheng. 2002;21(1):29-32.
15. Jaitovitch-Groisman I, Fotouhi-Ardakani N, Schecter RL, Woo A, Alaoui-Jamali MA, Batist G. Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz. J Biol Chem. 2000;275(43):33395-33403 (Pubitemid 30808549)
16. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431-435
17. Arbabi Bidgoli S, Djamali Zaverhei M, Mohagheghi M, et al. Differential Expression of uPA in Chronic Hepatitis B and C,Liver Cirrhosis and Hepatocellular Carcinoma: Comparison with Normal Liver Tissues and Liver Metastatic Tumors Int J Cancer Res. 2007;3(1):25-32. (Pubitemid 46805396)
18. nd ed.: Wiley Intersciences; 2002.
19. Leemans WF, Ter Borg MJ, de Man RA. Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther. 2007;26 Suppl 2:171-182
20. Takeuchi A, Kaneko S, Matsushita E, Urabe T, Shimoda A, Kobayashi K. Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines. J Gastroenterol. 1999;34(3):351-358 (Pubitemid 29332851)
21. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003;38(6):818-826 (Pubitemid 36613349)